Clasp Launches With $150m To Develop Personalized T-Cell Engagers

Dual Agents Target Oncogenes And HLA Proteins

Clasp Therapeutics, which emerged from labs at Johns Hopkins University and was incubated by a pair of venture capital investors, plans to achieve a clinical trial readout with its series A cash.

Start-up Funding Crowdfunding Investment Venture Capital Entrepreneurship Internet Business Technology Concept
Clasp will take at least one candidate into the clinic with its new funding • Source: Shutterstock

Clasp Therapeutics is developing next-generation T-cell engagers with the aim of developing off-the-shelf immuno-oncology therapeutics that have precise tumor targeting with limited on-target, off-tumor adverse events. And now with a $150m series A venture capital round announced on 20 March, the company plans to develop its first therapeutic candidates from preclinical all the way through initial clinical trial data.

Key Takeaways
  • Clasp Therapeutics launched with a $150m series A round to develop off-the-shelf T-cell engagers based on research conducted at Johns Hopkins University.

Cambridge, MA- and Rockville, MD-based Clasp emerged from the labs of cancer genetics specialist Bert Vogelstein and immuno-oncology researcher Drew...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Financing

Abivax Over The Moon As Obefazimod Storms Phase III

 
• By 

Stock shoots up over 460% on positive results in two ulcerative colitis trials of the oral first-in-class candidate.

Scrip M&A Podcast: Is Biopharma M&A In A Holding Pattern Or A ‘New Normal’

 
• By 

Scrip discusses the latest M&A activity and trends with CEO Shawn Titcomb of Allele Capital and Cheryl Reicin, a partner focused on international life sciences activity at Mintz.

Finance Watch: Sarepta’s Debt Woes Grow With Elevidys Shipment Pause

 
• By 

Public Company Edition: Sarepta restructured after stopping shipments of its Elevidys for some patients to ease future debt pressures, but now it has stopped shipments to all patients. Also, Madrigal secured up to $500m in new debt, Cogent closed a $230m offering and other financings.

Avalyn Raises $100m Series D To Advance Inhaled Pulmonary Fibrosis Candidates

 
• By 

Looking to improve on the efficacy and safety of Roche’s Esbriet and BI’s Ofev, Avalyn has inhalable formulations of those drugs in Phase IIb and Phase I, respectively.

More from Business

AZ Poised To Bring Self-Administered C5 Inhibitor To Market

 

Gefurulimab will give AstraZeneca a new option to compete against Argenx’s Vyvgart Hytrulo, which is available subcutaneously.

Roche Keen To Cut Out The Middle Men On US Pricing

 
• By 

The Swiss giant has been talking to the US government about selling medicines directly to patients.

Leo Looks To Grow In US After Hand Eczema Cream Approval

 
• By 

The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.